1. Scrip
  2. >>Business

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.

Scrip Five Must Know Things
audio roundup of selected content from Scrip's global team over the past week

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 April 2024, including: Genmab A/S buys into ADCs; Roivant Sciences set to take on AbbVie Inc. in uveitis; Ipsen SA signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda Therapeutics, Inc.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Genmab Adds To Sector ADC Buying Spree With $1.8bn ProfoundBio Acquisition" - Scrip, 3 April, 2024.)

(Also see "Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy" - Scrip, 2 April, 2024.)

(Also see "Ipsen Dives Back Into Dealmaking With First ADC Pact" - Scrip, 2 April, 2024.)

(Also see "Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative" - Scrip, 1 April, 2024.)

(Also see "All Over For Acorda After A Torrid Few Years" - Scrip, 3 April, 2024.)

Citeline · Scrip's Five Must-Know Things - 8 April 2024

Open Media

More from Business

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

First Quarter M&A Activity Rose On The Strength Of Three Deals

 
• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.